Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

News and Trends 7 Sep 2017

Scottish Oncology Biotech Aims for €96M IPO in the Nasdaq

Nucana Biomed has filed for a Nasdaq IPO in which it expects to raise up to $115M (€96M) to support the progression of its oncology pipeline. Nucana Biomed, a biotech based in Edinburgh, specializes in using phosphoramidate chemistry to upgrade nucleoside analogs, a common form of chemotherapy drugs. With its pipeline reaching late stages of […]

September 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Circassia pharmaceuticals astrazeneca pulmonary disease

News and Trends 7 Sep 2017

Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success

Circassia has positive Phase III results from its respiratory pipeline, great news for the company after abandoning its allergy immunotherapies due to clinical failure. Circassia Pharmaceuticals, based in Oxford, has reported a Phase III success with Duaklir, a drug combination for the treatment of chronic obstructive pulmonary disease (COPD). The trial was run by AstraZeneca, […]

September 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Sep 2017

MSD Offers €464M to Buy German Biotech Fighting Cancer with RNA

MSD is back in the RNA field with the acquisition of Rigontec, a German biotech harnessing RNA interference to make the immune system attack cancer cells. After selling selling Sirna Therapeutics three years ago for almost a tenth of the acquisition price, it seemed like MSD was out of the RNA field. However, the big […]

September 6, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Bicycle Therapeutics Bioverativ Hemophilia blood disorders

News and Trends 6 Sep 2017

A €344M Partnership will Develop Bicycle Drugs for Hemophilia

Bicycle Therapeutics has partnered with Bioverativ to develop a new class of drugs for patients with rare blood disorders like hemophilia and sickle cell disease. Bicycle Therapeutics, a money-magnet biotech founded by Greg Winter, has closed a deal with US firm Bioverativ for the discovery, development and commercialization of bicycle drugs for rare blood disorders. […]

September 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

GARDP Antibiotic Resistance Europe Germany

News and Trends 6 Sep 2017

Europe Gives the Antibiotic Resistance Fight a Major Cash Injection

Six European countries, the UK’s Wellcome Trust and South Africa have committed €56.5M to the GARDP to work on breaking antibiotic resistance. The Global Antibiotic Research and Development Partnership (GARDP) has received this week €56.5M of funding to boost its activity, focused in promoting the development of new antibiotics. The investment comes mainly from Germany, […]

September 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Inventiva fibrosis abbvie boehringer ingelheim

News and Trends 5 Sep 2017

French Biotech Lures Big Pharma with Fibrosis Treatments

This week, Inventiva has received a milestone payment from Boehringer Ingelheim and extended its collaboration with AbbVie. Today, Boehringer Ingelheim has decided today to take the next step forward and start development of the first candidate against idiopathic pulmonary fibrosis (IPF) from a research partnership with Inventiva. This has triggered a €2.5M payment for the French biotech, which is […]

September 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández

AMAL Therapeutics Cancer Vaccine Series B

News and Trends 5 Sep 2017

Swiss Biotech Raises €8M in First Closing of Series B to Develop Cancer Vaccines

AMAL Therapeutics has raised €8M to push its colorectal cancer vaccine ATP128 into clinical trials and keep developing its tumor vaccine pipeline. AMAL Therapeutics, a young biotech based in Geneva, is getting a boost for its pipeline of cancer vaccines thanks to a new funding round. The first tranche of its Series B fundraising has gathered €8M (CHF 8.8M) […]

September 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández

destiny pharma new antibiotics mrsa london stock1

News and Trends 4 Sep 2017

British Biotech Developing New Antibiotics Enters the London Stock Exchange

Destiny Pharma has started trading on the London Stock Exchange to support its search for new antibiotics that can fight resistant bacteria like MRSA. Destiny Pharma, based in Brighton, UK, has entered the AIM market of the London Stock Exchange with an initial placement of £15.3M (€16.7M), which put its starting market cap at £65.4M […]

September 4, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Allergan Heptares Therapeutics alzheimers

News and Trends 1 Sep 2017

Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal

Allergan’s partner Heptares Therapeutics has dosed the first patient with a GPCR drug to treat major symptoms of Alzheimer’s disease. A year ago, Allergan signed a massive deal of up to €3Bn with Heptares Therapeutics for the development of drugs that target G-protein-coupled receptors (GPCRs), a protein superfamily that currently comprises the target of around […]

September 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

CAR T cell therapy FDA approval cancer Novartis Kymriah CTL019

News and Trends 31 Aug 2017

The FDA Approves the First CAR-T Cell Therapy for Cancer

The FDA has approved Novartis’ CAR-T therapy Kymriah, opening the way for a new generation of cell therapy treatments against cancer. Novartis’ Kymriah (tisagenlecleucel), formerly known as CTL019, has become the first gene-modified cell therapy approved in the US. The FDA has approved the therapy for relapsing B-cell acute lymphoblastic leukemia (ALL) in children and young […]

August 31, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

probiodrug alzheimers disease mechanism of action

News and Trends 30 Aug 2017

German Scientists Publish New Mechanism of Action Against Alzheimer’s

Researchers at the German biotech Probiodrug have published today the detailed mechanism of action of a drug that might succeed in treating Alzheimer’s where many others have failed. Probiodrug is developing a therapeutic antibody with a unique mode of action against Alzheimer’s, PBD-C06. The company announced yesterday the publication in the Journal of Biological Chemistry of the detailed binding […]

August 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Aug 2017

Gilead’s €10Bn Buyout of Kite Pharma Shakes European CAR-T Stocks

European CAR-T stocks have jumped following Gilead’s announcement that it will acquire Kite Pharma, Novartis’ main competitor to launch the first therapy. Yesterday, Gilead bought a $11.9Bn (€9.9Bn) ticket to enter the final leg of the race to launch the first CAR-T therapy, a technology that is expected to change how cancer is treated. Despite the technology’s […]

August 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clara Rodríguez Fernández

About

Articles by Clara Rodríguez Fernández

Scottish Oncology Biotech Aims for €96M IPO in the Nasdaq

Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success

MSD Offers €464M to Buy German Biotech Fighting Cancer with RNA

A €344M Partnership will Develop Bicycle Drugs for Hemophilia

Europe Gives the Antibiotic Resistance Fight a Major Cash Injection

French Biotech Lures Big Pharma with Fibrosis Treatments

Swiss Biotech Raises €8M in First Closing of Series B to Develop Cancer Vaccines

British Biotech Developing New Antibiotics Enters the London Stock Exchange

Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal

The FDA Approves the First CAR-T Cell Therapy for Cancer

German Scientists Publish New Mechanism of Action Against Alzheimer’s

Gilead’s €10Bn Buyout of Kite Pharma Shakes European CAR-T Stocks

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Clara Rodríguez Fernández

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!